Latest news with #RxSight
Globe and Mail
9 hours ago
- Business
- Globe and Mail
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key metrics including sales of Light Delivery Devices ('LDD') along with a decline in total revenue across the organization. The Company also lowered its guidance for its full year financial performance, blaming the change in part on 'adoption challenges' that have caused an 'LDD stall.' Based on its financial performance, shares of RxSight fell by just under 38% on the same day. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
10 hours ago
- Business
- Business Wire
RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key metrics including sales of Light Delivery Devices ('LDD') along with a decline in total revenue across the organization. The Company also lowered its guidance for its full year financial performance, blaming the change in part on 'adoption challenges' that have caused an 'LDD stall.' Based on its financial performance, shares of RxSight fell by just under 38% on the same day. If you are a shareholder who suffered a loss, contact us to participate. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Upturn
2 days ago
- Business
- Business Upturn
RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Why is RxSight being Investigated? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Wire
3 days ago
- Business
- Business Wire
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed declines in Light Delivery Devices ('LDD') sales and light adjustable intraocular lenses ('LAL') utilization, along with an overall revenue decline. The Company lowered its guidance for full year 2025, claiming that 'Adoption challenges over the last few quarters have been a primary reason for the LDD stall.' Based on this news, shares of RxSight fell by 37.8% on July 9, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Associated Press
3 days ago
- Business
- Associated Press
RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 18, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ('RxSight' or 'the Company') (NASDAQ: RXST ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed declines in Light Delivery Devices ('LDD') sales and light adjustable intraocular lenses ('LAL') utilization, along with an overall revenue decline. The Company lowered its guidance for full year 2025, claiming that 'Adoption challenges over the last few quarters have been a primary reason for the LDD stall.' Based on this news, shares of RxSight fell by 37.8% on July 9, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/18/2025 12:41 PM/DISC: 07/18/2025 12:41 PM
